Texas
Cancer biologic therapy trials in Texas
140 cancer biologic therapy studies are recruiting participants at sites in 53 cities across Texas as of November 18, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Browse Texas by city
Cities with the most studies recruiting right now.
Houston
101 studies recruiting.
Dallas
46 studies recruiting.
San Antonio
35 studies recruiting.
Every Texas city with a recruiting study
By research area: Lymphoma (49), Lung Cancer (38), Breast Cancer (30), Melanoma (12), Prostate Cancer (6), Pancreatic Cancer (5).
Houston (101), Dallas (46), San Antonio (35), Fort Worth (18), Austin (16), Tyler (11), Sugar Land (10), El Paso (8), Lubbock (8), The Woodlands (7), Amarillo (6), Temple (6), Abilene (5), Baytown (5), Corpus Christi (5), Richardson (5), Conroe (4), League City (4), McAllen (4), Webster (4), Cypress (3), Flower Mound (3), Irving (3), Nassau Bay (3), Harlingen (2), Palestine (2), Weslaco (2), Wichita Falls (2), Allen (1), Arlington (1), Austin, TX 78758 (1), Beaumont (1), Bedford (1), Denison (1), Denton (1), Edinburg (1), Fredericksburg (1), Galveston (1), Garland (1), Grapevine (1), Humble (1), Laredo (1), Lewisville (1), Longview (1), McKinney (1), Midland (1), New Braunfels (1), Odessa (1), Paris (1), Pearland (1), Plano (1), Round Rock (1), Waco (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Texas
Basic details from each study's public record (the 12 most recently updated of 140). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Galveston
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Abilene · Dallas · Houston · and 1 more U.S. location
- Registry record
- NCT05564377 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Abilene · Amarillo · Dallas · and 6 more U.S. locations
- Registry record
- NCT06393374 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Dallas · El Paso · Houston · and 1 more U.S. location
- Registry record
- NCT06841354 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Texas on ClinicalTrials.gov.
Lung cancer: recently updated in Texas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Recruiting in
- Abilene · Austin · Dallas · and 4 more U.S. locations
- Registry record
- NCT06767514 · updated
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Houston
- Registry record
- NCT06422143 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Dallas · Houston · Tyler
- Registry record
- NCT06623422 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Texas on ClinicalTrials.gov.
Prostate cancer: recently updated in Texas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Dallas · Fort Worth · Richardson
- Registry record
- NCT03866382 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Texas on ClinicalTrials.gov.
Lymphoma: recently updated in Texas
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Austin · Corpus Christi · Dallas · and 5 more U.S. locations
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Houston · San Antonio
- Registry record
- NCT06337318 · updated
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Sugar Land
- Registry record
- NCT05947851 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Texas on ClinicalTrials.gov.
Pancreatic cancer: recently updated in Texas
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Houston
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Texas on ClinicalTrials.gov.
Ask about studies in Texas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections